Clinical trials: High Risk Cancer
Prostate Adenocarcinoma
CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer
The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free…
- Trial name
- NCT01985828
- Testing
- CyberKnife, Androgen Deprivation Therapy (ADT), Intensity Modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Wake Forest University Health Sciences
Subtotal Gastrectomy, Stomach Cancer
Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis
Erythromycin has a prokinetic effect through Motilin receptor. It evokes migrating motor complex with longer and stronger contraction.
- Trial name
- NCT01659619
- Testing
- Erythromycin
- Where
- South Korea
- Volunteers
- 114 people
- Sponsor
- The Catholic University of Korea
Localized Prostate Carcinoma
24 Gy in One Fraction Urethral-sparing "HDR Like" SBRT for Prostate Cancer
Patients with prostate cancer who are candidates for stereotactic radiotherapy to the prostate and seminal vesicles will undergo staging exams, which will include prostate specific membrane antigen (PSMA) positron emission…
- Trial name
- PRO-FAST (NCT05936736)
- Testing
- prostate SBRT
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- IRCCS San Raffaele
Hydatidiform Mole
RCT on the Efficacy of Methotrexate for the Prevention of GTD
A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.
- Trial name
- NCT01984099
- Testing
- Methotrexate, Vitamin B Complex
- Where
- Philippines
- Volunteers
- 99 people
- Sponsor
- University of the Philippines
Prostate Cancer
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
This is a pilot multimodality treatment approach trial with androgen deprivation therapy in combination with docetaxel chemotherapy followed by radical prostatectomy in patients with newly diagnosed high-risk and oligometastatic…
- Trial name
- NCT03358563
- Testing
- Docetaxel, Degarelix, Bicalutamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Primary Central Nervous System Lymphoma
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma
This study will evaluate the safety and efficacy of high-dose rituximab combined with temozolomide in the treatment of patients with Primary Central Nervous System Lymphomas (PCNSL).
- Trial name
- NCT02113007
- Testing
- Rituximab plus Temozolomide
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- SCRI Development Innovations, LLC
Diffuse Large B-cell Lymphoma
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP…
- Trial name
- frontMIND (NCT04824092)
- Testing
- Tafasitamab, Lenalidomide, Rituximab
- Where
- 307 sites in United States, Argentina and 27 more
- Volunteers
- 899 people
- Sponsor
- Incyte Corporation
BRCA1 Mutation, Breast Cancer
Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. The use of recombinant human chorionic gonadotropin may prevent breast cancer in premenopausal women with BRCA1 mutations.
- Trial name
- NCT00700778
- Testing
- recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method
- Where
- 3 sites in United States, Austria
- Volunteers
- 2 people
- Sponsor
- Fox Chase Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
- Trial name
- NCT00053118
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer
Short-course HIPEC in Advanced Epithelial Ovarian Cancer
This is an open-label, multicenter, single-arm, feasibility phase 2 trial on safety and efficacy of short-course regimen of intra-operative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the time of fast-track interval…
- Trial name
- NCT02249013
- Testing
- Cytoreductive Surgery (CRS), Hyperthermic Intraperitoneal Chemotherapy (HIPEC), Neoadjuvant Chemotherapy (NACT)
- Volunteers
- 15 people
- Sponsor
- Professor Fernando Figueira Integral Medicine Institute
Prostate Cancer
High-intensity Focused Ultrasound Study
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary…
- Trial name
- NCT03927924
- Testing
- High-intensity focused ultrasound
- Where
- Hong Kong
- Volunteers
- 5 people
- Sponsor
- Chinese University of Hong Kong
Breast Neoplasms
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients
The primary objective of this study is to assess the pathological Complete Response (pCR) rate by treatment arm (according to Chevallier criteria).
- Trial name
- SATIN (NCT00485979)
- Testing
- larotaxel (XRP9881), docetaxel, trastuzumab
- Where
- 8 sites in Belgium, Brazil and 6 more
- Volunteers
- 330 people
- Sponsor
- Sanofi
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma
- Trial name
- NCT03845296
- Testing
- Rucaparib
- Where
- 950 sites in United States
- Volunteers
- 64 people
- Sponsor
- SWOG Cancer Research Network
Non-Hodgkin's Lymphoma
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
About 60% of patients with DLBCL can be cured with a chemotherapy program. It is called RCHOP-21 (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone). It is given once every 3 weeks, for 18 weeks.
- Trial name
- NCT00712582
- Testing
- Etoposide, carboplatin, ifosfamide, Rituximab, Ifosfamide, Etoposide, Carboplatin, Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
High Intensity Functional Training in the Rehabilitation of Cancer Survivors
The primary aim of this study is to investigate changes in health related quality of life (HRQoL) and cancer-related fatigue (CRF) following a 16-weeks of HIFT as a part of the rehabilitation of cancer survivors.
- Trial name
- NCT04001127
- Testing
- High Intensity Functional Training
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Andreas Lund Hessner
Immunity, Innate, Colorectal Cancer
Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy
This study will measure the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in high risk subjects (Quebec risk categories P2, P3 and P4) scheduled for colonoscopy.
- Trial name
- ANKA-HR (NCT03249727)
- Testing
- IVDD for NK cell activity in whole blood
- Where
- 3 sites in Canada
- Volunteers
- 396 people
- Sponsor
- ATGen Canada Inc
Chronic Myeloid Leukemia
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia…
- Trial name
- NCT00854841
- Testing
- Dasatinib and Imatinib
- Sponsor
- Pusan National University Hospital
Neuroblastoma, Sarcoma
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody A1G4 with BCG may kill more tumor cells.
- Trial name
- NCT00003023
- Testing
- BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Precancerous Condition, Stage 0 Melanoma
Lovastatin in Treating Patients At High Risk of Melanoma
The use of lovastatin may slow disease progression in patients at high risk of melanoma. It is not yet known whether lovastatin is more effective than a placebo in treating patients at high risk of melanoma.
- Conditions
- Precancerous Condition, Stage 0 Melanoma, Stage I Melanoma, Stage II Melanoma
- Trial name
- NCT00462280
- Testing
- lovastatin, biopsy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Study of Ductal Lavage in Women at High Risk for Breast Cancer
RATIONALE: Collecting samples of fluid using ductal lavage and nipple aspiration from participants at high risk for breast cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and…
- Trial name
- NCT00429988
- Testing
- fluorescence in situ hybridization, polymerase chain reaction, proteomic profiling
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.